Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Assets: 2020-2024

Historic Other Non-Current Assets for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $1.3 million.

  • Apellis Pharmaceuticals' Other Non-Current Assets rose 278.69% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 278.69%. This contributed to the annual value of $1.3 million for FY2024, which is 3.06% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Other Non-Current Assets stood at $1.3 million for FY2024, which was up 3.06% from $1.3 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Other Non-Current Assets ranged from a high of $1.6 million in FY2021 and a low of $1.3 million during FY2020.
  • Moreover, its 3-year median value for Other Non-Current Assets was $1.3 million (2023), whereas its average is $1.3 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Other Non-Current Assets increased by 23.46% in 2021, and later dropped by 18.55% in 2022.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Other Non-Current Assets stood at $1.3 million in 2020, then increased by 23.46% to $1.6 million in 2021, then declined by 18.55% to $1.3 million in 2022, then rose by 2.83% to $1.3 million in 2023, then climbed by 3.06% to $1.3 million in 2024.